This lead to FDA approval for ipilimumab in 2011.[18] FDA also approved Vemurafenib in 2011 and dabrafenib for melanoma patients with the BRAF V600E mutation.[19–21] Currently, the standard of care for patients with metastatic melanoma with the BRAF V600E mutation is a combination of BRAF and MEK inhibitors.[22,23] After introduction of these new therapies the utilization of HD IL2 has reduced for melanoma patients. Here, BRAF is linked to melanoma.